Issue 10, 2011

Are pyridazines privileged structures?

Abstract

One can estimate that about 50% of all the drug molecules used in medicine contain a phenyl ring which can be substituted or not. The bioisosteric replacement of these phenyl rings by the corresponding pyridazine rings opens an access to several thousands of diaza analogues presenting more interaction possibilities, lower Log P values and improved crystalline salts. The use of pyridazine scaffolds in place of phenyl scaffolds entails additional interaction possibilities. Another interest of pyridazines is their capacity to act as original functional surrogates. Thus, aminopyridazines can be used as carboxamide, as well as amine surrogates. Finally, the many examples of pyridazines used either as a structural element or as a main scaffold, justify largely their status as privileged structures

Graphical abstract: Are pyridazines privileged structures?

Article information

Article type
Review Article
Submitted
15 Mar 2011
Accepted
17 Apr 2011
First published
10 Jun 2011

Med. Chem. Commun., 2011,2, 935-941

Are pyridazines privileged structures?

C. G. Wermuth, Med. Chem. Commun., 2011, 2, 935 DOI: 10.1039/C1MD00074H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements